Lung cancer is the most common cause of cancer-related death in the United States, with >160,000 new cases per year.1,2 Over the past several years, there have been remarkable developments in the diagnosis, staging, and treatment of lung cancer, including chest CT scan screening for high-risk individuals with proven survival benefit,3 minimally invasive surgical approaches,4 and endobronchial ultrasound (EBUS) as the primary means of mediastinal staging.5 All of these innovations combined will have a dramatic impact on the quality and quantity of life in lung cancer victims.